Trial Profile

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brexucabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
Indications Mantle-cell lymphoma
Focus Therapeutic Use
Acronyms ZUMA-2 Cohort3
Sponsors Kite Pharma

Most Recent Events

09 Dec 2024 Results presented in a Gilead Sciences media release.
09 Dec 2024 According to Gilead Sciences media release, primary analysis from this study were presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
06 Dec 2024 According to a John Theurer Cancer Center media release, data from this trial will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH) to be held in San Diego, California, from December 7-10, 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com